** Sleep apnea device maker Inspire Medical Systems' shares INSP.N fall 2.9% to $175.72 in morning trade
** Co late on Monday reported Q4 adj EPS of $1.15, above Wall Street est of 73 cents - data compiled by LSEG
** INSP said they have "made steady progress" toward the full launch of sleep apnea device Inspire V during Q4
** Wells Fargo says the launch is slower than expected due to hurdles at its U.S and Mexico manufacturing plants
** Scaling up production on a new U.S. line takes time, as management aims to minimize disruption to production of the older device Inspire IV while producing Inspire V, brokerage says
** Brokerage says a civil investigation by the U.S. justice department related to allegations of false information about co's devices submitted to the agency might hurt the stock
** Brokerages Truist, Morgan Stanley and Wells Fargo cut their PTs on INSP
** Stock was down 1.3% in 2024
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。